{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:14:53Z","timestamp":1793445293026,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005620","name":"North Carolina GlaxoSmithKline Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005105","name":"Australian Renewable Energy Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004358","name":"Samsung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003122","name":"Ferring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","giejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastrointestinal Endoscopy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.gie.2018.08.018","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T15:45:39Z","timestamp":1534952739000},"page":"887-898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["The emerging role of histologic disease activity assessment in ulcerative colitis"],"prefix":"10.1016","volume":"88","author":[{"given":"Rish K.","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.","family":"Lauwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gie.2018.08.018_bib1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gie.2018.08.018_bib2","unstructured":"US Department of Health and Human Services. Ulcerative Colitis: Clinical Trial Endpoints Guidance for Industry. Available at: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM515143.pdf. Accessed March 17,\u00a02018."},{"key":"10.1016\/j.gie.2018.08.018_bib3","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gie.2018.08.018_bib4","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1097\/01.MIB.0000437044.43961.00","article-title":"Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?","volume":"19","author":"Wolff","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib5","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/MIB.0b013e318281f4ae","article-title":"Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission","volume":"19","author":"Feagins","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11894-015-0477-6","article-title":"Understanding endoscopic disease activity in IBD: how to incorporate it into practice","volume":"18","author":"Christensen","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.gie.2018.08.018_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.giec.2014.03.005","article-title":"Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity","volume":"24","author":"Walsh","year":"2014","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"10.1016\/j.gie.2018.08.018_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000443133","article-title":"Mucosal healing - how deep is enough?","volume":"34","author":"Iacucci","year":"2016","journal-title":"Dig Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gie.2018.08.018_bib10","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gie.2018.08.018_bib11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gie.2018.08.018_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gie.2018.08.018_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A\u00a0review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gie.2018.08.018_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2017.08.025","article-title":"Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set","volume":"16","author":"Ma","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gie.2018.08.018_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","article-title":"Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up","volume":"65","author":"Bryant","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2016.50","article-title":"Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study","volume":"111","author":"Zenlea","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gie.2018.08.018_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOG.0000000000000082","article-title":"The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease","volume":"30","author":"Moss","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.gie.2018.08.018_bib18","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","article-title":"Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/ibd.21925","article-title":"Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation","volume":"18","author":"Baars","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib20","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2013.02.030","article-title":"Histologic markers of inflammation in patients with ulcerative colitis in clinical remission","volume":"11","author":"Rosenberg","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gie.2018.08.018_bib21","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cgh.2014.06.020","article-title":"Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission","volume":"12","author":"Guardiola","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gie.2018.08.018_bib22","doi-asserted-by":"crossref","unstructured":"Magro F, Lopes J, Borralho P, et al. Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut. Epub 2018 Feb 3.","DOI":"10.1136\/gutjnl-2017-315545"},{"key":"10.1016\/j.gie.2018.08.018_bib23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A\u00a0reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/bmj.1.4979.1315","article-title":"Biopsy studies in ulcerative colitis","volume":"4979","author":"Truelove","year":"1956","journal-title":"BMJ"},{"key":"10.1016\/j.gie.2018.08.018_bib25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MIB.0b013e318280e75f","article-title":"Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis","volume":"19","author":"Lemmens","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib26","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/ajg.2012.301","article-title":"Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing","volume":"107","author":"Bessissow","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gie.2018.08.018_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00000478-199808000-00008","article-title":"Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time","volume":"22","author":"Kleer","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.gie.2018.08.018_bib28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/BF02233941","article-title":"Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets","volume":"11","author":"Wright","year":"1966","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/gut.32.2.174","article-title":"Microscopic activity in ulcerative colitis: what does it mean?","volume":"32","author":"Riley","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/gast.2001.20912","article-title":"Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis","volume":"120","author":"Bitton","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gie.2018.08.018_bib31","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.dld.2017.08.041","article-title":"Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission","volume":"49","author":"Calafat","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5217\/ir.2018.16.1.55","article-title":"Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis","volume":"16","author":"Narang","year":"2018","journal-title":"Intest Res"},{"key":"10.1016\/j.gie.2018.08.018_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/1319-3767.80383","article-title":"Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study","volume":"17","author":"Azad","year":"2011","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.gie.2018.08.018_bib34","doi-asserted-by":"crossref","first-page":"O420","DOI":"10.1111\/codi.12725","article-title":"Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy","volume":"16","author":"Zezos","year":"2014","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.dld.2016.11.007","article-title":"Tissue and peripheral eosinophilia as predictors for disease outcome in children with ulcerative colitis","volume":"49","author":"Morgenstern","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib36","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.cgh.2017.02.016","article-title":"Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes","volume":"15","author":"Christensen","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gie.2018.08.018_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2036.2010.04537.x","article-title":"Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis","volume":"33","author":"Kruis","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gie.2018.08.018_bib38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gut.2008.154302","article-title":"Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, noninferiority trial","volume":"58","author":"Kruis","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib39","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/MIB.0000000000000736","article-title":"Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis","volume":"22","author":"Theede","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gie.2018.08.018_bib40","first-page":"305","article-title":"A\u00a0simplified Geboes score for ulcerative colitis","volume":"11","author":"Jauregui-Amezaga","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gie.2018.08.018_bib41","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1136\/gut.2005.086900","article-title":"Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis","volume":"55","author":"Nishio","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib42","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/ajg.2016.418","article-title":"Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis","volume":"111","author":"Park","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gie.2018.08.018_bib43","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1053\/j.gastro.2007.08.001","article-title":"Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study","volume":"133","author":"Gupta","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gie.2018.08.018_bib44","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.3748\/wjg.v20.i17.4980","article-title":"Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis","volume":"20","author":"Korelitz","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gie.2018.08.018_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gie.2018.08.018_bib46","doi-asserted-by":"crossref","unstructured":"Choi CR, Al Bakir I, Ding NJ, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large singlecentre study. Gut. Epub 2017 Nov 17.","DOI":"10.1136\/gutjnl-2017-314190"},{"key":"10.1016\/j.gie.2018.08.018_bib47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.gie.2017.07.028","article-title":"Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"86","author":"Flores","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gie.2018.08.018_bib48","first-page":"CD011256","article-title":"Histologic scoring indices for evaluation of disease activity in ulcerative colitis","volume":"5","author":"Mosli","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gie.2018.08.018_bib49","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1136\/gutjnl-2016-312722","article-title":"A\u00a0practical guide to assess the Nancy histological index for UC","volume":"65","author":"Marchal-Bressenot","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","article-title":"Development and validation of the Nancy histological index for UC","volume":"66","author":"Marchal-Bressenot","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/gutjnl-2015-310393","article-title":"Development and validation of a histological index for UC","volume":"66","author":"Mosli","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib52","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/gutjnl-2014-307536","article-title":"Reproducibility of histological assessments of disease activity in UC","volume":"64","author":"Mosli","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.gie.2018.08.018_bib53","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","article-title":"Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative","volume":"8","author":"Bryant","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gie.2018.08.018_bib54","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.humpath.2007.10.012","article-title":"Evaluation of site-specific and seasonal variation in colonic mucosal eosinophils","volume":"39","author":"Polydorides","year":"2008","journal-title":"Hum Pathol"}],"container-title":["Gastrointestinal Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016510718329389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016510718329389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:58:11Z","timestamp":1762163891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016510718329389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0016510718329389"],"URL":"https:\/\/doi.org\/10.1016\/j.gie.2018.08.018","relation":{},"ISSN":["0016-5107"],"issn-type":[{"value":"0016-5107","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of histologic disease activity assessment in ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"Gastrointestinal Endoscopy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gie.2018.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Society for Gastrointestinal Endoscopy","name":"copyright","label":"Copyright"}]}}